Is Sansure Biotech (SHSE:688289) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about
Sansure Biotech Inc. (688289.SH): The actual controller and director proposed a mid-term dividend.
On July 17th, Gelon Hui reported that Mr. Dai Lizhong, the actual controller and chairman of Sansure Biotech Inc. (688289.SH), proposed a mid-term dividend plan for 2024, based on the total share capital of the company minus the shares in the company's repurchase special securities account, to distribute a cash dividend of 2.50 yuan (tax-included) per 10 shares to all shareholders, subject to the profit distribution principle stipulated in the Company Law and the premise of ensuring the normal operation and long-term development of the company. The specific profit distribution plan shall be formulated and implemented by the company in combination with its own operating conditions.
SanSure Biotech Inc.'s announcement on voluntarily disclosing the performance forecast for the first half of 2024.
Sansure Biotech Inc. (688289.SH) received a government subsidy of RMB 46.998 million.
Sansure Biotech Inc. (688289.SH) announced that it has recently received a government subsidy of RMB 46.998 million in industry support funds allocated by the Business and Market Supervision Bureau of Hunan Xiangjiang New Area Management Committee. This subsidy is revenue-related and has been included in the company's annual profit and loss.
Sansure Biotech Inc. (688289.SH): The net income in the first half of the year is expected to increase by 64% to 80% compared with the same period last year.
On July 3, Gelonhui reported that Sansure Biotech Inc. (688289.SH) estimates that its revenue will reach 710,000,000 yuan in the first half of 2024, an increase of 282,304,200 yuan or 66% compared to the same period last year. The net income attributable to the owners of the parent company is expected to be between 150,000,000 yuan and 165,000,000 yuan in the first half of 2024, an increase of 58,323,900 yuan to 73,323,900 yuan compared to the same period last year, with a year-on-year increase of 64% to 80%.
Is Sansure Biotech Inc.'s (SHSE:688289) Stock Price Struggling As A Result Of Its Mixed Financials?
Sansure Biotech (SHSE:688289) has had a rough month with its share price down 12%. We, however decided to study the company's financials to determine if they have got anything to do with the price d
Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification
Sansure Biotech's (SHA:688289) mycobacterium tuberculosis DNA fluorescence diagnostic kit received a European Union's In Vitro Diagnostic Regulation or IVDR certificate, the company said in its filing
Sansure Biotech Inc. (688289.SH): its tuberculosis nucleic acid detection kit has obtained CE certification in the European Union.
Sansure Biotech Inc. (688289.SH) announced on June 11th that its Mycobacterium tuberculosis DNA Fluorescence Diagnostic Kit (PCR-Fluorescence Probing), used for qualitative detection of tuberculosis in human sputum samples of suspected or confirmed tuberculosis infections, has recently obtained the European Union CE IVDR certification.
Sansure Biotech Inc. (688289.SH): Relevant products have obtained the registration certificate of medical instruments.
On June 6th, Gelunhui announced that Sansure Biotech Inc. (stock code: 688289.SH) has recently received the Medical Device Registration Certificate issued by the National Medical Products Administration for its HBV RNA quantitative detection kit (PCR-fluorescent probe method) for hepatitis B virus. HBV RNA quantitative detection kit (PCR-fluorescent probe method) is the eighth kit registered by the company for medical devices in the field of screening and diagnosis of viral hepatitis. The detection sensitivity of the kit can reach 50copies/mL, and the linear range is 1.0E+02 copies.
Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing mor
Sansure Biotech Inc. (688289.SH) annual equity distribution in 2023: 2 yuan per 10 shares. Equity registration on June 7.
Sansure Biotech Inc. (688289.SH) issued the Annual Equity Distribution Implementation Notice for 2023, which will implement equity distribution...
Shengxiang Biotech (688289.SH) plans to establish a new joint venture with the Industrial Fund to focus on the field of rapid drug sensitivity testing
Shengxiang Biology (688289.SH) announced that the company intends to partner with the relevant party Hunan Xiangjiang Shengxiang Biological Industry Fund...
Shengxiang Biology (688289.SH): Plans to invest in Hunan Shengwei Sumin with related parties and transfer shares in the participating company FirstLight
On May 8, Ge Longhui Biotech (688289.SH) announced that it plans to jointly invest in the joint venture Hunan Shengwei Sumin Biotechnology Co., Ltd. (“Hunan Shengwei Sumin”) with the related party Hunan Xiangjiang Shengxiang Biological Industry Fund (limited partnership), of which the company's total investment amount is RMB 53.33 million. At the same time, the company plans to transfer 21.69% of the shares in the participating company FirstLightDiagnostics, Inc. (“FirstLight”) to a wholly-owned subsidiary of the joint venture with a consideration of 2,215,8
Sansure Biotech's (SHSE:688289) Earnings Quality Is Low
After announcing weak earnings, Sansure Biotech Inc.'s (SHSE:688289) stock was strong. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.
Sansure Biotech Inc.'s (SHSE:688289) Shares May Have Run Too Fast Too Soon
Sansure Biotech Inc.'s (SHSE:688289) price-to-sales (or "P/S") ratio of 10.8x might make it look like a strong sell right now compared to the Medical Equipment industry in China, where around half of
Shengxiang Biotech (688289.SH): Net profit of 81.025 million yuan in the first quarter increased 35.01% year-on-year
On April 26, Ge Longhui (688289.SH) released its report for the first quarter of 2024, achieving operating income of 391 million yuan, an increase of 100.31%; net profit attributable to shareholders of listed companies of 81.025 million yuan, an increase of 35.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 73.755 million yuan, an increase of 1962.06% year on year; basic earnings per share of 0.14 yuan.
Shengxiang Biotech (688289.SH) posted an advance increase. The net profit for the first quarter is expected to be 81.4891 million yuan, an increase of 35.79% over the previous year
Shengxiang Biotech (688289.SH) announced that the company expects to become a parent company in the first quarter of 2024...
Sansure Biotech (SHSE:688289) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Investors Will Want Sansure Biotech's (SHSE:688289) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expandi
Zhu Jinwei, shareholder of Shengxiang Biotech (688289.SH), reduced his holdings by 2% and the reduction period expired
Zhitong Finance App News, Shengxiang Biotech (688289.SH) issued an announcement. As of the disclosure date of this announcement, shareholder Zhu Jinwei had reduced his holdings of the company's shares by a total of 11.754,600 shares through centralized bidding transactions, accounting for 2% of the company's total shares. The time range for this holdings reduction plan has expired, and implementation has been completed.
No Data